Menu

AAAS Insiders Petition to Revoke Honors of Sexual Harassers

The organization says it’s working on a policy.

Aug 24, 2018
Shawna Williams
ISTOCK, ARTISEER

Update (September 17): AAAS announced September 15 that it has adopted a new revocation policy for elected fellows “in cases of proven scientific misconduct, serious breaches of professional ethics, or when the Fellow in the view of AAAS no longer merits the status of Fellow.”

Using the hashtag #TimesUpAAAS, 36 researchers recognized by the American Association for the Advancement of Science for their science communication work posted an open letter asking the society not to bestow honors on those “who have engaged in harassment and discrimination.” This group of AAAS Leshner fellows—along with hundreds of other signatories, including numerous AAAS fellows—urges the organization to devise a sexual harassment policy that applies not just to elected fellows but other honorees as well, and that requires honorees to “disclose any ongoing investigations as well as prior findings of professional misconduct.” 

As a Twitter campaign under the hashtag gained steam on Tuesday (August 21), the American Association for the Advancement of Science announced that “Harassment has no place in science. That’s why we’re working on a revocation policy for elected @AAAS Fellows, currently under consideration by the AAAS Council.”

The #TimesUpAAAS campaign is not the first effort to pressure the organization to change its policies around sexual harassment by honorees. Last month, neuroscientist BethAnn McLaughlin of Vanderbilt University started a petition calling on AAAS to kick out fellows found guilty in sexual harassment or assault investigations. A spokesperson for the organization told The Scientist at the time that it was in the process of developing a policy around sexual harassment by fellows. 

See “Petition Asks AAAS to Remove Fellows With Sexual Harassment Records

While details of the policy have not been announced, Tuesday’s tweet from AAAS prompted a declaration of victory from McLaughlin, who is also petitioning the National Academy of Sciences to take similar action. She now urges readers to pressure the National Institutes of Health and lawmakers to prohibit sexual harassers from receiving training grants, using NIH funds for travel, or serving on funding boards.

See “Petition Asks National Academy of Sciences to Boot Sexual Harassers

March 2019

Going Under

Dissecting the effects of anesthetics

Marketplace

Sponsored Product Updates

The Complex Biology of Macrophages: Origins, Functions, and Activation States
The Complex Biology of Macrophages: Origins, Functions, and Activation States
Download this poster from R&D Systems for a detailed overview of macrophage markers, functions, development, specialization, and activation!
A Guide to Measuring Drug-Target Residence Times with Biochemical Assays
A Guide to Measuring Drug-Target Residence Times with Biochemical Assays
Download this guide from BellBrook Labs to learn about how to use Transcreener® biochemical assays to measure drug-target residence times, complete with examples and case studies!
Beckman Coulter Life Sciences To Launch New Product Via Live Stream Event
Beckman Coulter Life Sciences To Launch New Product Via Live Stream Event
After visiting labs around the world to identify ways to advance its industry-leading cell counting technology, Beckman Coulter Life Sciences will host a live streaming event on March 26 at 10 a.m. EDT / 7 a.m. PDT to announce its latest product innovation.  
Cybrexa Therapeutics to Present First Data and Unveil Details for its alphalex™-PARP Inhibitor Lead Candidate CBX-11 at AACR Annual Meeting 2019
Cybrexa Therapeutics to Present First Data and Unveil Details for its alphalex™-PARP Inhibitor Lead Candidate CBX-11 at AACR Annual Meeting 2019
Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor targeting platform, today announced that Vishwas Paralkar, PhD, Chief Scientific Officer of Cybrexa, will present the first set of preclinical data supporting its alphalex™-PARP inhibitor lead candidate, CBX-11, at the American Association for Cancer Research (AACR) Annual Meeting 2019, being held March 29 – April 3 in Atlanta, Georgia. At the meeting, the Company will unveil the FDA-approved poly ADP-ribose polymerase (PARP) inhibitor conjugated in CBX-11.